2013年4月23日訊 /生物谷BIOON/ --近日，賽諾菲（Sanofi）疫苗事業部——賽諾菲-巴斯德（Sanofi Pasteur）宣布，6合1兒科疫苗Hexyon/Hexacima獲歐盟委員會（EC）批准，用於6周及以上兒童的初次免疫（primary vaccination）及加強免疫（ booster vaccination）。
Hexyon/Hexacima是唯一一種全液體（fully liquid）即用型（ready-to-use）疫苗，用於嬰幼兒預防白喉、破傷風、百日咳、B型肝炎、小兒麻痺症及由B型流感嗜血桿菌引發的侵入性感染。（生物谷bioon.com）
英文原文：SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe
Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN
and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima? (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima? is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima? in Eastern European countries by Sanofi Pasteur.
"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."